Method to Reduce Oxalate Concentration by Administration of Oxalate Oxidase Crystals
The invention relates to methods to prevent, treat, or slow the progression of a disorder associated with elevated oxalate concentration, the method comprising administering oxalate oxidase crystals, cross-linked crystals, or compositions containing those crystals to an individual. Oxalate oxidase crystals and compositions for administration to an individual are also provided, including stabilized crystals, such as cross-linked crystals of oxalate oxidase.
1 . A method of reducing oxalate concentration in a mammal, the method comprising administration of oxalate oxidase crystals to the mammal.
2 . The method of claim 1 , wherein the oxalate oxidase crystals are stabilized.
3 . The method of claim 2 , wherein the oxalate oxidase crystals comprise oxalate oxidase covalently linked by a cross-linking agent.
4 . The method of claim 3 , wherein the cross-linking agent is multifunctional.
5 . The method of claim 3 , wherein the cross-linking agent is bifunctional.
6 . The method of claim 5 , wherein the bifunctional cross-linking agent is glutaraldehyde.
7 . The method of claim 1 , wherein the administration is via the upper gastrointestinal tract.
8 . The method of claim 7 , wherein the administration is oral.
9 . The method of claim 1 , wherein the administration is via an extracorporeal device.
10 . The method of claim 9 , wherein the device is a dialysis device.
11 . The method of claim 1 , wherein the oxalate oxidase crystals are administered as a suspension, dry powder, capsule, or tablet.
12 . The method of claim 1 , further comprising detecting oxalate concentration in a biological sample of the mammal.
13 . The method of claim 12 , wherein the biological sample is urine, blood, plasma, or serum.
14 . The method of claim 1 , wherein the administration of oxalate oxidase crystals results in a reduction of oxalate concentration of at least 10%.
15 . The method of claim 14 , wherein administration of oxalate oxidase crystals results in a reduction of oxalate concentration of at least 20%.
16 . The method of claim 15 , wherein administration of oxalate oxidase crystals results in a reduction of oxalate concentration of at least 30%.
17 . The method of claim 14 , wherein the reduction is measured in biological sample is chosen from urine, blood, plasma, and serum.
18 . A method to treat a disorder associated with elevated oxalate concentration in a mammal, comprising administering oxalate oxidase crystals to the mammal.
19 . The method of claim 18 , wherein the disorder is chosen from a kidney disorder, bone disorder, liver disorder, gastrointestinal disorder, and pancreatic disorder.
20 . The method of claim 18 , wherein the disorder is chosen from primary hyperoxaluria, enteric hyperoxaluria, idiopathic hyperoxaluria, ethylene glycol poisoning, cystic fibrosis, inflammatory bowel disease, urolithiasis, and nephrolithiasis.
21 . The method of claim 1 , wherein the oxalate oxidase is recombinantly produced.
22 . A method for treating an oxalate-related disorder in an individual, comprising providing an endogenous polypeptide that is capable of catalyzing the conversion of oxalic acid and molecular oxygen to carbon dioxide and hydrogen peroxide to an individual, wherein the polypeptide is a stabilized crystal.
23 . The method of claim 22 , wherein the polypeptide is covalently cross-linked by a cross-linking agent.
24 . The method of claim 23 , wherein the cross-linking agent is glutaraldehyde.
25 . An oxalate oxidase crystal cross-linked with a multifunctional cross-linking agent.
26 . The cross-linked oxalate oxidase crystal according to claim 25 where the cross-linking agent is glutaraldehyde.
27 . The cross-linked oxalate oxidase crystal according to claim 26 where the cross-linking agent is glutaraldehyde and is present in a final concentration of at least about 0.1%.
28 . The cross-linked oxalate oxidase crystal according to claim 27 where the cross-linking agent is glutaraldehyde and is present in a final concentration of 4%.
29 . The cross-linked oxalate oxidase crystal according to claim 27 where the cross-linking agent is glutaraldehyde and is present in a final concentration of 1%.
30 . The crystal of claim 25 , wherein the oxalate oxidase retains at least 70% of the activity of the corresponding soluble oxalate oxidase.
31 . The crystal of claim 25 , wherein the oxalate oxidase retains at least 95% of the activity of the corresponding soluble oxalate oxidase.
32 . The crystal of claim 25 , wherein the oxalate oxidase retains at least 98% of the activity of the corresponding soluble oxalate oxidase.
33 . A pharmaceutical composition comprising the crystal of claim 25 .
34 . A method of treatment, comprising administering an effective dose of the pharmaceutical composition of claim 33 .